News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bavarian Nordic (BAVA.CO) Announces Execution Of Option On Freeze-Dried IMVAMUNE


4/22/2014 9:03:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

KVISTGAARD, Denmark, April 22, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised an option at a value of USD 21.9 million under the existing development contract for freeze-dried IMVAMUNE smallpox vaccine. This will fund the transfer of the already validated manufacturing process to a commercial manufacturing line with a larger capacity.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES